BioMed Nexus

Bicycle Shelves Padcev Challenger • Aldeyra's 3rd CRL • Jensen Huang's $1T Flex

Rhythm's PDUFA lands Friday, Lilly's obesity pill decision looms, and GTC puts pharma AI under the microscope.

Pharma’s GPU Arms Race Accelerates: Roche vs. Lilly at GTC

ACIP meets Wednesday, Rhythm’s PDUFA lands Friday, and China clears the first commercial BCI.

Lilly Flags GLP-1 Impurity • Hims Exits Compounding • Sana Durability

Sana validates the T1D cure thesis at 14 months, ACIP meets Wednesday, and Rhythm's PDUFA lands Friday.

Lilly's Compounding Crackdown • Ultragenyx Hits Ph3 • Novo's Asset Slide

A new tirzepatide-B12 impurity escalates the GLP-1 compounding war as Pfizer winds down its biotech incubator.

BridgeBio’s LGMD Breakthrough • Stryker Cyberattack • Vima Adds $40M

FORTIFY Phase 3 data positions BBP-418 as the first LGMD therapy while Evotec cuts 800 jobs and CAR-T competition intensifies.

FDA Sets “Trial-Free” Precedent for Ultra-Rare Disease • BioNTech Founders Pivot • Hims Lands Ozempic

Leucovorin approved using literature evidence alone as BioNTech shares drop and GLP-1 telehealth tensions ease.

Japan Approves First iPS Therapies • Xenon’s Record Epilepsy Data • FDA Eases Biosimilar Path

Azetukalner posts the strongest pivotal epilepsy efficacy ever as Vertex advances its kidney disease filing.

Servier Buys Day One for $2.5B • CBER Chief Prasad to Exit • Lonza’s $3B CDMO Pivot

MDA conference opens as MiniMed’s weak IPO and Zealand’s petrelintide data reshape the obesity race.

J&J’s 55-Day FDA Approval • CVS & Google Launch AI Health Platform • TrumpRx Stalls

Tec-Dara combo sets a new myeloma benchmark as Atavistik closes a $160M raise.

Prime Tests Two-Patient FDA Approval • Moderna’s $2.25B Patent Deal • Glenmark Flovent Win

Ultra-rare regulatory precedent meets a record LNP settlement as generics pressure hits respiratory.

Teva Lands $400M Blackstone Deal • J&J's Fifth Fast Track • UCB's $1.1B CD19 Bet

Non-dilutive capital structures dominate as TL1A race heats up.

FDA Splits Gene Therapy: uniQure Rejected, Intellia Hold Lifted

Sham-controlled Phase 3 required for AMT-130 • Roche BTK Phase 3 win • ITC probes China biotech.

Week in Review: YUVIWEL Approved | Generate's Rough Debut | 44-Day Precedent

Ascendis wins achondroplasia approval with PRV, Generate IPO falls 21%, Key March PDUFAs.

FDA's 44-Day Approval | Sarepta CEO Exits | BioMarin Pulls Roctavian

Zongertinib sets a new regulatory speed record, Generate prices $400M IPO, Gene therapy reality check.

GSK’s $950M PAH Bet: 35Pharma Deal Signals Activin Race

HS235 clinical push vs Winrevair heats up, MacroGenics lorigerlimab pause, Medtronic MiniMed IPO momentum

Novo Cuts GLP-1 Prices 50% Ahead of Federal Pricing Push

CagriSema miss reshapes obesity race • BREAKWATER doubles OS • MiniMed IPO roadshow

Gilead Pays 79% Premium for Arcellx | FDA Drafts Plausible Mechanism Pathway | Vir $1.7B Deal

CAR-T scarcity trade ignites, Ultra-rare approvals reshaped, ASCO GU positioning begins

FDA Approves Bysanti | The Single-Trial Era Begins

CStone's UK win, Compass nears NDA, Mayne's margin pivot

FDA Signals Shift to Single-Trial Standard | Insmed Guides to $1B | Madrigal Nears Blockbuster

Makary outlines single pivotal pathway | Brinsupri breakout | Eversense 365 launches with twiist

FDA Reverses Moderna RTF | J&J Onshores Cell Therapy

PDUFA set for August 5 | $1B U.S. manufacturing pivot | Merck inks Mayo AI pact.

Ocular Superiority vs. 25% Drop • Danaher Buys Masimo • Medtronic PFA Surge

Retina trial paradox • $9.9B diagnostic deal • Cardiac ablation grows 80% • J&J monthly dosing approved.

Roche Kidney Breakthrough • Sanofi's $2.4B Ocular Gamble • Medtronic Earnings

Gazyva first-ever PMN win • OCUL faces make-or-break readout today • India's $240M reshoring play.

Weekly Recap: FDA Rejects Moderna & Disc • BridgeBio Phase 3 Win • HRT Label Shift

Surrogate scrutiny intensifies • Oral achondroplasia data raises switching pressure • Lilly builds $1.5B ahead of PDUFA.

BridgeBio Phase 3 Win • FDA HRT Label Shift • Universal Flu Trial

Oral dwarfism pill outpaces prior injectable data • Hormone boxed warnings removed • Seres & Ultragenyx cut staff

Merck Keytruda Win, Madrigal $4.4B Deal, Jobs Report Surprise

First immunotherapy for platinum-resistant ovarian cancer, Viking confirms Phase 3 timeline, Healthcare adds 82k jobs.